Literature DB >> 23775960

African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?

Debasish Sundi1, Ashley E Ross, Elizabeth B Humphreys, Misop Han, Alan W Partin, H Ballentine Carter, Edward M Schaeffer.   

Abstract

PURPOSE: Active surveillance (AS) is a treatment option for men with very low-risk prostate cancer (PCa); however, favorable outcomes achieved for men in AS are based on cohorts that under-represent African American (AA) men. To explore whether race-based health disparities exist among men with very low-risk PCa, we evaluated oncologic outcomes of AA men with very low-risk PCa who were candidates for AS but elected to undergo radical prostatectomy (RP). PATIENTS AND METHODS: We studied 1,801 men (256 AA, 1,473 white men, and 72 others) who met National Comprehensive Cancer Network criteria for very low-risk PCa and underwent RP. Presenting characteristics, pathologic data, and cancer recurrence were compared among the groups. Multivariable modeling was performed to assess the association of race with upgrading and adverse pathologic features.
RESULTS: AA men with very low-risk PCa had more adverse pathologic features at RP and poorer oncologic outcomes. AA men were more likely to experience disease upgrading at prostatectomy (27.3% v 14.4%; P < .001), positive surgical margins (9.8% v 5.9%; P = .02), and higher Cancer of the Prostate Risk Assessment Post-Surgical scoring system (CAPRA-S) scores. On multivariable analysis, AA race was an independent predictor of adverse pathologic features (odds ratio, [OR], 3.23; P = .03) and pathologic upgrading (OR, 2.26; P = .03).
CONCLUSION: AA men with very low-risk PCa who meet criteria for AS but undergo immediate surgery experience significantly higher rates of upgrading and adverse pathology than do white men and men of other races. AA men with very low-risk PCa should be counseled about increased oncologic risk when deciding among their disease management options.

Entities:  

Mesh:

Year:  2013        PMID: 23775960      PMCID: PMC3739860          DOI: 10.1200/JCO.2012.47.0302

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

Review 1.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

2.  Does race affect postoperative outcomes in patients with low-risk prostate cancer who undergo radical prostatectomy?

Authors:  M J Resnick; D J Canter; T J Guzzo; B M Brucker; M Bergey; S S Sonnad; A J Wein; S B Malkowicz
Journal:  Urology       Date:  2008-12-18       Impact factor: 2.649

3.  Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.

Authors:  Isaac J Powell; Cathryn H Bock; Julie J Ruterbusch; Wael Sakr
Journal:  J Urol       Date:  2010-03-17       Impact factor: 7.450

4.  Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.

Authors:  J W Moul; R R Connelly; R M Mooneyhan; W Zhang; I A Sesterhenn; F K Mostofi; D G McLeod
Journal:  J Urol       Date:  1999-08       Impact factor: 7.450

Review 5.  Active surveillance for prostate cancer: a systematic review of the literature.

Authors:  Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway
Journal:  Eur Urol       Date:  2012-06-07       Impact factor: 20.096

6.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

7.  Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.

Authors:  Chad R Ritch; Belinda F Morrison; Greg Hruby; Kathleen C Coard; Richard Mayhew; William Aiken; Mitchell C Benson; James M McKiernan
Journal:  BJU Int       Date:  2012-10-26       Impact factor: 5.588

8.  Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.

Authors:  Christopher L Amling; Robert H Riffenburgh; Leon Sun; Judd W Moul; Raymond S Lance; Leo Kusuda; Wade J Sexton; Douglas W Soderdahl; Timothy F Donahue; John P Foley; Andrew K Chung; David G McLeod
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

9.  Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group.

Authors:  Stephen J Freedland; William J Aronson; Christopher J Kane; Joseph C Presti; Christopher L Amling; David Elashoff; Martha K Terris
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

10.  Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup.

Authors:  J I Epstein; M Carmichael; A W Partin; P C Walsh
Journal:  J Urol       Date:  1993-06       Impact factor: 7.450

View more
  84 in total

1.  Urological cancer: Poorer prostate cancer outcomes in African American men.

Authors:  Vanessa Marchesi
Journal:  Nat Rev Clin Oncol       Date:  2013-07-02       Impact factor: 66.675

2.  Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.

Authors:  Michael S Leapman; Stephen J Freedland; William J Aronson; Christopher J Kane; Martha K Terris; Kelly Walker; Christopher L Amling; Peter R Carroll; Matthew R Cooperberg
Journal:  J Urol       Date:  2016-06-25       Impact factor: 7.450

Review 3.  Current trends and new frontiers in focal therapy for localized prostate cancer.

Authors:  Melissa H Mendez; Daniel Y Joh; Rajan Gupta; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2015-06       Impact factor: 3.092

Review 4.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  Cansu Karakas; Cassie Wang; Fangming Deng; Hongying Huang; Dongwen Wang; Peng Lee
Journal:  Am J Clin Exp Urol       Date:  2017-11-09

5.  Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer.

Authors:  Kelvin A Moses; Heather Orom; Alicia Brasel; Jacquelyne Gaddy; Willie Underwood
Journal:  Urol Oncol       Date:  2016-05-06       Impact factor: 3.498

6.  Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.

Authors:  Yaw A Nyame; Adam B Murphy; Diana K Bowen; Gregory Jordan; Ken Batai; Michael Dixon; Courtney M P Hollowell; Stephanie Kielb; Joshua J Meeks; Peter H Gann; Virgilia Macias; Andre Kajdacsy-Balla; William J Catalona; Rick Kittles
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

7.  Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter?

Authors:  Kelvin A Moses; Heather Orom; Alicia Brasel; Jacquelyne Gaddy; Willie Underwood
Journal:  Urology       Date:  2016-09-22       Impact factor: 2.649

Review 8.  Active surveillance for low-risk prostate cancer.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

Review 9.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

10.  Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men.

Authors:  Isaac J Powell; Fawn D Vigneau; Cathryn H Bock; Julie Ruterbusch; Lance K Heilbrun
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-06       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.